{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:43:45Z","timestamp":1792133025612,"version":"4.4.0"},"reference-count":103,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Endometrial cancer occurs in up to 29% of women before 40 years of age. Seventy percent of these patients are nulliparous at the time. Decision making regarding fertility preservation in early stage endometrial cancer (ES-EC) is, therefore, a big challenge since the decision between the risk of cancer progression and a chance to parenthood needs to be made. Sixty-two percent of women with complete remission of ES-EC after fertility-sparing treatment (FST) report to have a pregnancy wish which, if not for FST, they would not be able to fulfil. The aim of this review was to identify and summarise the currently established biomolecular and genetic prognostic factors that can facilitate decision making for FST in ES-EC. A comprehensive search strategy was carried out across four databases; Cochrane, Embase, MEDLINE, and PubMed; they were searched between March 1946 and 22nd December 2022. Thirty-four studies were included in this study which was conducted in line with the PRISMA criteria checklist. The final 34 articles encompassed 9165 patients. The studies were assessed using the Critical Appraisal Skills Program (CASP). PTEN and POLE alterations we found to be good prognostic factors of ES-EC, favouring FST. MSI, CTNNB1, and K-RAS alterations were found to be fair prognostic factors of ES-EC, favouring FST but carrying a risk of recurrence. PIK3CA, HER2, ARID1A, P53, L1CAM, and FGFR2 were found to be poor prognostic factors of ES-EC and therefore do not favour FST. Clinical trials with bigger cohorts are needed to further validate the fair genetic prognostic factors. Using the aforementioned good and poor genetic prognostic factors, we can make more confident decisions on FST in ES-EC.<\/jats:p>","DOI":"10.3390\/ijms23052653","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T20:11:14Z","timestamp":1646079074000},"page":"2653","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial Cancer (ES-EC): A Systematic Review"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-0995","authenticated-orcid":false,"given":"Panayiotis","family":"Tanos","sequence":"first","affiliation":[{"name":"Institute of Applied Health Sciences, University of Aberdeen & Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-6961","authenticated-orcid":false,"given":"Savvas","family":"Dimitriou","sequence":"additional","affiliation":[{"name":"Aberdeen Fertility Centre, NHS Grampian and University of Aberdeen, Aberdeen AB25 2ZN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4269-4269","authenticated-orcid":false,"given":"Giuseppe","family":"Gullo","sequence":"additional","affiliation":[{"name":"In Vitro Fertilization Unit (IVF Unit), Azienda Ospedaliera Ospedali Riuniti, Villa Sofia Cervello, 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4695-4630","authenticated-orcid":false,"given":"Vasilios","family":"Tanos","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Aretaeio Hospital, Nicosia 2024, Cyprus"},{"name":"St. Georges\u2019 Medical School, University of Nicosia, Nicosia 2408, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2020, July 29). GLOBOCAN 2018: Estimated Cancer Incidence, Mortality and Prevalence WORLDWIDE in 2018. Available online: http:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/24-Corpus-uteri-fact-sheet.pdf."},{"key":"ref_2","unstructured":"(2020, November 17). World Health Organization; International Agency for Research on Cancer (IARC); Global Cancer Observatory (GCO). Available online: https:\/\/gco.iarc.fr."},{"key":"ref_3","unstructured":"(2020, November 17). The Netherlands Cancer Registry, the Netherlands Comprehensive Cancer Organisation (IKNL). Available online: https:\/\/www.iknl.nl\/netherlands-cancer-registry."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000506803","article-title":"Closed vs. Open Oocyte Vitrification Methods Are Equally Effective for Blastocyst Embryo Transfers: Prospective Study from a Sibling Oocyte Donation Program","volume":"85","author":"Gullo","year":"2020","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.fertnstert.2016.07.1066","article-title":"How does closed system vitrification of human oocytes affect the clinical outcome? A prospective, observational, cohort, noninferiority trial in an oocyte donation program","volume":"106","author":"Papatheodorou","year":"2016","journal-title":"Fertil. Steril."},{"key":"ref_6","first-page":"3","article-title":"Novelties of ultrasound imaging for endometrial cancer preoperative workup","volume":"112","author":"Capozzi","year":"2020","journal-title":"Minerva Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s10815-017-1010-7","article-title":"GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF\/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: A prospective randomized control trial","volume":"34","author":"Prapas","year":"2017","journal-title":"J. Assist. Reprod. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Schuurman, T., Zilver, S., Samuels, S., Schats, W., Amant, F., van Trommel, N., and Lok, C. (2021). Fertility-Sparing Surgery in Gynecologic Cancer: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13051008"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated Genomic Characterization of Endometrial Carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"ref_10","unstructured":"Gospodarowicz, M.K., O\u2019Sullivan, B., and Sobin, H. (2006). Studies investigating prognostic factors: Conduct and evaluation. Prognostic Factors in Cancer, Wiley-Liss. [3rd ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1053\/j.seminoncol.2010.04.001","article-title":"The Importance of Identifying and Validating Prognostic Factors in Oncology","volume":"37","author":"Halabi","year":"2010","journal-title":"Semin. Oncol."},{"key":"ref_12","first-page":"2","article-title":"Psychological impact of gynecological diseases: The importance of a multidisciplinary approach","volume":"30","author":"Valenti","year":"2018","journal-title":"J. Gynaecol. Obstet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/0090-8258(83)90111-7","article-title":"Two pathogenetic types of endometrial carcinoma","volume":"15","author":"Bokhman","year":"1983","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2008.10.032","article-title":"Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer","volume":"112","author":"Jongen","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/jnci\/88.16.1127","article-title":"Case\u2014Control Study of Endogenous Steroid Hormones and Endometrial Cancer","volume":"88","author":"Potischman","year":"1996","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/0046-8177(95)90204-X","article-title":"P53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumourigenesis","volume":"26","author":"Sherman","year":"1995","journal-title":"Hum. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/2159-8290.CD-11-0039","article-title":"High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability","volume":"1","author":"Cheung","year":"2011","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.1158\/0008-5472.CAN-11-0549","article-title":"PIK3R1 (p85\u03b1) Is Somatically Mutated at High Frequency in Primary Endometrial Cancer","volume":"71","author":"Urick","year":"2011","journal-title":"Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"984013","DOI":"10.1155\/2010\/984013","article-title":"Genetics of Endometrial Cancers","volume":"2010","author":"Okuda","year":"2010","journal-title":"Obstet. Gynecol. Int."},{"key":"ref_20","first-page":"2500","article-title":"Mutation of the PTEN tumour suppressor gene in endometrial hyperplasias","volume":"58","author":"Maxwell","year":"1998","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ygyno.2013.10.033","article-title":"Prevalence of occult gynecologic malignancy at the time of risk reducing and nonprophylactic surgery in patients with Lynch syndrome","volume":"132","author":"Lachiewicz","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.path.2016.04.006","article-title":"Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Uterine Tumours","volume":"9","author":"Ritterhouse","year":"2016","journal-title":"Surg. Pathol. Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jmoldx.2020.11.006","article-title":"An Integrative DNA Sequencing and Methylation Panel to Assess Mismatch Repair Deficiency","volume":"23","author":"Oldfield","year":"2021","journal-title":"J. Mol. Diagn."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Salvesen, H., Stefansson, I., Kretzschmar, E., Gruber, P., Macdonald, N., Ryan, A., Jacobs, I., Akslen, L., and Das, S. (2004). Significance of PTEN alterations in endometrial carcinoma: A population-based study of mutations, promoter methylation and PTEN protein expression. Int. J. Oncol., 25.","DOI":"10.3892\/ijo.25.6.1615"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00432-011-1103-0","article-title":"Roles of genetic variants in the PI3K and RAS\/RAF pathways in susceptibility to endometrial cancer and clinical outcomes","volume":"138","author":"Wang","year":"2012","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/aogs.13740","article-title":"Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence","volume":"99","author":"Imboden","year":"2020","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Cavaliere, A.F., Perelli, F., Zaami, S., D\u2019Indinosante, M., Turrini, I., Giusti, M., Gullo, G., Vizzielli, G., Mattei, A., and Scambia, G. (2021). Fertility Sparing Treatments in Endometrial Cancer Patients: The Potential Role of the New Molecular Classification. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222212248"},{"key":"ref_28","first-page":"3254","article-title":"PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma","volume":"58","author":"Levine","year":"1998","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ygyno.2019.03.247","article-title":"Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer","volume":"153","author":"Veneris","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Haruma, T., Nagasaka, T., Nakamura, K., Haraga, J., Nyuya, A., Nishida, T., Goel, A., Masuyama, H., and Hiramatsu, Y. (2018). Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0195655"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12881-019-0936-2","article-title":"POLE mutations improve the prognosis of endometrial cancer via regulating cellular metabolism through AMF\/AMFR signal transduction","volume":"20","author":"Li","year":"2019","journal-title":"BMC Med. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<60::AID-IJC9>3.0.CO;2-3","article-title":"Microsatellite instability and hMLH1\/hMSH2 expression in young endometrial car-cinoma patients: Associations with family history and histopathology","volume":"86","author":"Parc","year":"2000","journal-title":"Int. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"370.e1","DOI":"10.1016\/j.ajog.2020.10.003","article-title":"Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer","volume":"224","author":"Chung","year":"2021","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/modpathol.2017.15","article-title":"CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence","volume":"30","author":"Kurnit","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-15-2878","article-title":"Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer\u2014Combined Analysis of the PORTEC Cohorts","volume":"22","author":"Stelloo","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"533","DOI":"10.21873\/anticanres.13145","article-title":"The Role of KRAS in Endometrial Cancer: A Mini-Review","volume":"39","author":"Sideris","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/IGC.0b013e31826b1110","article-title":"Racial Differences in Oncogene Mutations Detected in Early-Stage Low-Grade Endometrial Cancers","volume":"22","author":"Cote","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/path.4056","article-title":"Use of mutation profiles to refine the classification of endometrial carcinomas","volume":"228","author":"McConechy","year":"2012","journal-title":"J. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1158\/1078-0432.CCR-06-1375","article-title":"PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia","volume":"12","author":"Hayes","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 Is an Independent Prognostic Factor in Endometrial Cancer: Association With Outcome in a Large Cohort of Surgically Staged Patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/modpathol.2012.174","article-title":"ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas","volume":"26","author":"Werner","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s12885-016-2631-4","article-title":"L1CAM as a prognostic marker in stage I endometrial cancer: A validation study","volume":"16","author":"Smogeli","year":"2016","journal-title":"BMC Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/modpathol.2011.110","article-title":"FGFR2 alterations in endometrial carcinoma","volume":"24","author":"Gatius","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8713","DOI":"10.1073\/pnas.0803379105","article-title":"Drug-sensitive FGFR2 mutations in endometrial carcinoma","volume":"105","author":"Dutt","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7158","DOI":"10.1038\/sj.onc.1210529","article-title":"Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes","volume":"26","author":"Pollock","year":"2007","journal-title":"Oncogene"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/jnci\/92.11.924","article-title":"Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers","volume":"92","author":"Mutter","year":"2000","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jamaoncol.2017.0619","article-title":"Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies","volume":"3","author":"Ryan","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10669","DOI":"10.1158\/0008-5472.CAN-05-2620","article-title":"High Frequency of Coexistent Mutations of PIK3CA and PTEN Genes in Endometrial Carcinoma","volume":"65","author":"Oda","year":"2005","journal-title":"Cancer Res."},{"key":"ref_51","unstructured":"(2021, December 20). The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. Available online: http:\/\/prisma-statement.org\/."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Imboden, S., Nastic, D., Ghaderi, M., Rydberg, F., Rau, T.T., Mueller, M.D., Epstein, E., and Carlson, J.W. (2019). Phenotype of POLE-mutated endometrial cancer. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214318"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/sj.bjc.6604278","article-title":"Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells","volume":"98","author":"Konecny","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ygyno.2006.07.015","article-title":"Expression of the epidermal growth factor system in endometrioid endometrial cancer","volume":"104","author":"Poulsen","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/sj.bjc.6605805","article-title":"Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer","volume":"103","author":"Mori","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Byron, S.A., Gartside, M., Powell, M.A., Wellens, C.L., Gao, F., Mutch, D.G., Goodfellow, P.J., and Pollock, P.M. (2012). FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features. PLoS ONE, 7.","DOI":"10.1371\/annotation\/0bfaecca-0f87-43fe-97cc-f2ae3ddeb6d5"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2014.06.010","article-title":"beta-Catenin mutations in recurrent FIGO IA grade I endometrioid en-dometrial cancers","volume":"134","author":"Myers","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_58","first-page":"263","article-title":"Roles of EGFR and KRAS Mutations in the Treatment of Patients with Non-Small-Cell Lung Cancer","volume":"36","author":"Langer","year":"2011","journal-title":"Pharm. Ther."},{"key":"ref_59","first-page":"150960","article-title":"Clinical Relevance of KRAS in Human Cancers","volume":"2010","author":"Drabek","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/jcp.2008.056101","article-title":"Molecular pathology of endometrial carcinoma: Practical aspects from the diagnostic and therapeutic viewpoints","volume":"62","author":"Llobet","year":"2009","journal-title":"J. Clin. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1111\/jog.12442","article-title":"Carcinogenic mechanisms of endometrial cancer: Involvement of genetics and epigenetics","volume":"40","author":"Banno","year":"2014","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3892\/or_00000523","article-title":"Epigenetic DNA hypermethylation: Clinical applications in endometrial cancer","volume":"22","author":"Banno","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ygyno.2017.02.031","article-title":"FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology\/Gynecologic Oncology Group study","volume":"145","author":"Jeske","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_64","first-page":"449","article-title":"Chromatin remodeling, SWI\/SNF (BAF) complex, ARID1A, ARID1B, development, pluripotency, cell identity","volume":"9","author":"Pagliaroli","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Levine","year":"2013","journal-title":"Nature"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility","volume":"38","author":"Ronnett","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3892\/or.2015.4421","article-title":"ARID1A gene mutation in ovarian and endometrial cancers","volume":"35","author":"Takeda","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Schirmer, U., Fiegl, H., Pfeifer, M., Zeimet, A.G., M\u00fcller-Holzner, E., Bode, P.K., Tischler, V., and Altevogt, P. (2013). Epigenetic regulation of L1CAM in endometrial carcinoma: Comparison to cancer\u2013testis (CT-X) antigens. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-156"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1016\/j.ejca.2014.07.014","article-title":"L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: Pooled PORTEC trial results","volume":"50","author":"Bosse","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/modpathol.2015.147","article-title":"Prognostic significance of L1CAM expression and its association with mutant P53 expression in high-risk endometrial cancer","volume":"29","author":"Stelloo","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"266.e1","DOI":"10.1016\/j.ajog.2012.08.011","article-title":"Regression, relapse, and live birth rates with fertil-ity-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: A systematic review and me-ta-analysis","volume":"207","author":"Gallos","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1159\/000209324","article-title":"Fertility sparing in EC","volume":"67","author":"Tangjitgamol","year":"2009","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ejca.2012.09.017","article-title":"Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with EC (KGOG 2002)","volume":"49","author":"Park","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.3802\/jgo.2019.30.e47","article-title":"Six months response rate of combined oral medroxyproges-terone\/levonorgestrel-intrauterine system for early-stage endometrial cancer in young women: A Korean Gynecolog-ic-Oncology Group Study","volume":"30","author":"Kim","year":"2019","journal-title":"J. Gynecol. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ygyno.2017.07.120","article-title":"Effects of metformin on endometrial cancer: Systematic review and meta-analysis","volume":"147","author":"Meireles","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fmed.2018.00240","article-title":"Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature","volume":"5","author":"Tock","year":"2018","journal-title":"Front. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.fertnstert.2013.11.028","article-title":"Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: Systematic review and meta-analysis","volume":"101","author":"Koskas","year":"2014","journal-title":"Fertil. Steril."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"La Rubia, E.C.-D., Martinez-Garcia, E., Dittmar, G., Gil-Moreno, A., Cabrera, S., and Colas, E. (2020). Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9061900"},{"key":"ref_79","unstructured":"Menichini, D., Forte, G., Orr\u00f9, B., Gullo, G., Unfer, V., and Facchinetti, F. (2020). The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review. Int. J. Vitam. Nutr. Res., 1\u20138."},{"key":"ref_80","first-page":"485","article-title":"Myo-inositol: From induction of ovulation to menopausal disorder management","volume":"67","author":"Gullo","year":"2015","journal-title":"Minerva Ginecol."},{"key":"ref_81","first-page":"e932722","article-title":"D-chiro-inositol Induces Ovulation in Non-Polycystic Ovary Syndrome (PCOS), Non-Insulin-Resistant Young Women, Likely by Modulating Aromatase Expression: A Report of 2 Cases","volume":"22","author":"Espinola","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"8866","DOI":"10.1038\/s41598-021-88329-x","article-title":"Myoinositol plus \u03b1 lactalbumin supplementation, insulin resistance and birth outcomes in women with gestational diabetes mellitus:a randomized, controlled study","volume":"11","author":"Corrado","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Gullo, G., Etrusco, A., Cucinella, G., Perino, A., Chiantera, V., Lagan\u00e0, A.S., Tomaiuolo, R., Vitagliano, A., Giampaolino, P., and Noventa, M. (2021). Fertility-Sparing Approach in Women Affected by Stage I and Low-Grade Endometrial Carcinoma: An Updated Overview. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111825"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","article-title":"Endometrial cancer","volume":"387","author":"Morice","year":"2016","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.2008.19.8150","article-title":"Safety of Ovarian Preservation in Premenopausal Women With Endometrial Cancer","volume":"27","author":"Wright","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_86","first-page":"3005","article-title":"PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics","volume":"4","author":"Risinger","year":"1998","journal-title":"Clin. Cancer Res."},{"key":"ref_87","first-page":"3935","article-title":"Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies","volume":"57","author":"Tashiro","year":"1997","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/aogs.13587","article-title":"Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review","volume":"98","author":"Travaglino","year":"2019","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/carcin\/bgz046","article-title":"Genome-wide DNA methylation profile of early-onset endometrial cancer: Its correlation with genetic aberrations and comparison with late-onset endometrial cancer","volume":"40","author":"Makabe","year":"2019","journal-title":"Carcinogenesis"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00404-019-05145-5","article-title":"Molecular expression characteristics confirm the malignancy concealed by morphological alterations in endometrial cancer after fertility-preserving treatment","volume":"299","author":"Hu","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/modpathol.2011.208","article-title":"Clinical assessment of PTEN loss in endometrial carcinoma: Immunohistochemistry outperforms gene sequencing","volume":"25","author":"Djordjevic","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1600-0463.2009.02467.x","article-title":"Biologic markers in endometrial cancer treatment","volume":"117","author":"Engelsen","year":"2009","journal-title":"APMIS"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1002\/cncr.28152","article-title":"Molecular pathogenesis of endometrial cancers in patients with Lynch syndrome","volume":"119","author":"Huang","year":"2013","journal-title":"Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_95","first-page":"397","article-title":"Mismatch repair protein expression in colorectal cancer","volume":"4","author":"Kheirelseid","year":"2013","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1200\/JCO.2006.08.2107","article-title":"Microsatellite Instability and Epigenetic Inactivation of MLH1 and Outcome of Patients With Endometrial Carcinomas of the Endometrioid Type","volume":"25","author":"Zighelboim","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc.2015.12","article-title":"A panoply of errors: Polymerase proofreading domain mutations in cancer","volume":"16","author":"Rayner","year":"2016","journal-title":"Nat. Cancer"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1097\/PGP.0000000000000496","article-title":"International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group","volume":"38","author":"Cho","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/his.14015","article-title":"Incorporation of molecular characteristics into endometrial cancer management","volume":"76","author":"Vermij","year":"2020","journal-title":"Histopathology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1097\/IGC.0000000000000493","article-title":"European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients","volume":"25","author":"Rodolakis","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Johansen, G., Dahm-K\u00e4hler, P., Staf, C., R\u00e5destad, A.F., and Rodriguez-Wallberg, K.A. (2020). A Swedish Nationwide prospective study of oncological and reproductive outcome following fertility-sparing surgery for treatment of early stage epithelial ovarian cancer in young women. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07511-y"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejogrb.2021.06.007","article-title":"The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review","volume":"263","author":"Piatek","year":"2021","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_103","first-page":"1355","article-title":"Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: A systematic review and meta-analysis","volume":"dmab041","author":"Cappelletti","year":"2021","journal-title":"Hum. Reprod. Updat."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/5\/2653\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:29:23Z","timestamp":1760135363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/5\/2653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":103,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["ijms23052653"],"URL":"https:\/\/doi.org\/10.3390\/ijms23052653","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]}}}